Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
310 results about "Phosphatidyl ethanolamine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Phosphatidylethanolamine (PE) is an important phospholipid that makes up cell membranes and organelle membranes. It is also called cephalin because it is abundant in the brain, spinal cord, and other nervous tissues.
Hyaluronic Acid Compound, Hydrogel Thereof and Joint Treating Material
ActiveUS20080193538A1Good biological adaptabilityPowder deliveryBiocideBiocompatibility TestingHyaluronic acid
A hyaluronic acid compound which is a reaction product between hyaluronic acid and a phosphatidyl ethanolamine. This compound has biocompatibility and bio-safety, and can be formed into a hydrogel or molded form having a certain shape. Making use of these properties, it is used to treat a knee joint, prevent the accretion of a tissue after an operation and keep a skin wet.
Owner:TEIJIN LTD
Cucurbitacin lipsome preparation method and formulation
InactiveCN1504191AHigh encapsulation efficiencyOrganic active ingredientsDigestive systemCucurbitacin BMedicine
The invention relates to a cucurbitacin liposome composition and its preparation, which has rather high encapsulation efficiency, and can be administered through vein, muscle, oral and nasal. The constituent percentage by weight of the composition are, cucurbitacin BE or cucurbitacin B 0.001-0.1%, phospholipids 0.1-10%, cholesterin 0-5%, the phospholipids can be lecithin, di-stearoyl phosphatidyl choline, di- palmityl phosphatidyl choline, di-oleoyl phosphatidyl choline, di- palmityl phosphatidyl ethanolamine, di-stearoyl phosphatidylglycerol. The preparation according to the invention can be prepared in the form of injection, oral liquid, syrup, drop and nasal spray
Owner:SHENYANG PHARMA UNIVERSITY
Paclitaxel nano micelle and application thereof
InactiveCN102133172AIncreased intracellular uptakeEnhanced inhibitory effectOrganic active ingredientsPharmaceutical delivery mechanismDequalinium chlorideEthanolamine synthesis
The invention discloses paclitaxel nano micelle and an application thereof. The paclitaxel nano micelle is prepared from the following components shown in the following (1), (2) or (3): (1) a carrier and paclitaxel, wherein the carrier is a mixture of polyethylene glycol-distearoyl phosphatidyl ethanolamine (PEG-DSPE), D-alpha-tocopherol polyethylene glycol 1000 succinate (TPGS) and dequalinium chloride; (2) a carrier and the paclitaxel, wherein the carrier is a mixture of the PEG-DSPE and the TPGS; and (3) a carrier and the paclitaxel, wherein the carrier is the PEG-DSPE. After the functionalized paclitaxel nano micelle disclosed by the invention is orally taken, the paclitaxel can penetrate through a barrier of gastrointestinal tract, thus the multi-drug resistance (MDR) of drug-resistant breast cancer is overcome. The oral formulation of the functionalized paclitaxel nano micelle disclosed by the invention can avoid the anaphylactic response, can be applied to numerous cancer patients and is also suitable for MDR tumors at the same time, thereby having great advantage compared with the traditional intravenous injection formulation.
Owner:PEKING UNIV
Compositions and methods for less immunogenic protein-lipid complexes
InactiveUS20090053297A1Lower titerLow immunogenicityPeptide/protein ingredientsMicroencapsulation basedLipid formationHalf-life
The present invention provides compositions and methods for reducing the immunogenicity and increasing the circulating half-life of therapeutic proteins such as Factor VIII. The compositions comprise lipidic structures such as liposomes, micelles and cochleates comprising a negatively charged lipid and polyethylene glycol derivatized phosphatidyl ethanolamine.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Fluorescence nanometer probe and preparation method thereof
The invention relates to a fluorescence nanometer probe, comprising an inner core formed by polyglycolide lactide, a middle layer formed by phospholipid surrounding on the surface of the inner core and a shell formed by distearoyl phosphatidyl ethanolamine-polyethylene glycol which contains amino or carboxyl and partially penetrates through the middle layer, wherein indocyanine green is dispersed in the inner core. According to the invention, a core-shell structure is formed to ensure that the indocyanine green is wrapped in the polyglycolide lactide, therefore, the indocyanine green is effectively avoided from being aggregated and decomposed and the stability is increased; and the wrapped indocyanine green has a near-infrared fluorescence characteristic to ensure that the background fluorescence penetrating tissues is small and then can be relatively accurately applied to bioluminescence labeling.
Owner:SHENZHEN INST OF ADVANCED TECH CHINESE ACAD OF SCI
Multifunctional nano probe for multimodal images and photothermal therapy of liver cancer and application of multifunctional nano probe
ActiveCN103721271AHigh molecular weightImprove spatial resolutionEnergy modified materialsX-ray constrast preparationsSide effectLight energy
Owner:FUZHOU HOSPITAL FOR INFECTIOUS DISEASE
Amphoteric liposomes
ActiveUS20110076322A1Improve stabilityIncrease serum stabilityOrganic active ingredientsBiocideAmphiphileSerum ige
Owner:BIONTECH DELIVERY TECH GMBH
Method for finishing fabric through plant essential oil thermosensitive liposomes
The invention discloses a method for finishing fabric through plant essential oil thermosensitive liposomes. The method comprises the following steps: mixing and stirring tea tree essential oil, menthol and artemisia vulgaris oil to obtain a natural fragrant antibacterial agent; dissolving the natural fragrant antibacterial agent in a phosphate buffered solution; mixing natural phosphatide, phosphatidylcholine, glyceryl phosphatide, phosphatidyl ethanolamine, phosphatidylserine and phosphatidic acid, adding cholesterol, dissolving the mixture into chloroform, pouring into a container, and evaporating at the room temperature until a layer of uniform thin film is formed on the container wall; adding the phosphate buffered solution of the natural fragrant antibacterial agent into the container coated with the thin film in ultrasonic water bath, and performing ultrasonic oscillation to obtain a thermosensitive liposome suspension liquor; adding an adhesive into the thermosensitive liposome suspension liquor, and stirring at the room temperature until the adhesive agent is completely dissolved, so as to obtain a thermosensitive fragrant antibacterial finishing agent; immersing and rolling fabric into the finishing liquid, immersing and rolling for the second time, and finally finishing and shaping the fabric by adopting a freezing and drying method.
Owner:新诚达时装(安徽)有限公司
Diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being
InactiveUS20060286183A1Rapid weight lossAppetite suppressantBiocidePeptide/protein ingredientsDietary supplementMental health
Compositions and methods for administering to the diet of humans a composition for inducing rapid weight loss, controlling appetite, managing stress and supporting mental well-being, supporting relaxation, and combating fatigue. A diet supplement comprising Calcium and Potassium double salt of Garcinia Cambogia Extract supplying 60% Hydroxycitric Acid, Gymnema Sylvestre Leaf Extract, Rhodiola Rosea Root Extract, Theanine, Astaxanthin Algae Extract, Chromium Polynicotinate, Hoodia Gordonii, N-olyl-phosphatidyl ethanolamine (NOPE) / EGCG blend, Vinpocetine, Russian Tarragon Extract, N-acetyl tyrosine, and Withania Somnifera Root Extract is provided. Said diet supplement is comprised of at least Hoodia Gordonii wherein the extract does not contain any extract from the root of the plant.
Owner:SMARTBURN FORMULATIONS LTD
Gene-ordrug-carrying-carrying ultrasonic microvesicle contrast-media and preparing method thereof
InactiveCN1814305AIncrease concentrationStable in natureNMR/MRI constrast preparationsLipid formationSide effect
This invention discloses an ultrasonic microbubble contrast agent of carrier gene, it includes microbubble, fluorocarbon gas, gene or medicine. Microbubble wall is made up by lipid bielement, fluorocarbon gas is encapsulated in it, gene or medicine entrapped in microbubble envelope. This invention also discloses its preparation method, two stearyl phosphatidylcholine, two palmitoyl phosphatidyl ethanolamine, sapn-60, glycerol, phosphate buffer solution and gene or medicine is mixed as proper proportion for mechanical oscillations. The property of carry gene or medicine microbubble is stable, particle diameter disperses equally, local tissue medicine concentration can be obviously advanced though effect of transonic breaking microbubble, and curative effect is advanced and side effect can be reduced. Flushing and dilution of blood to gene and medicine can be prevented when used in body, and also prevent gene or medicine from degrading by nuclease in cycle to ensure that lot of gene and medicine can be transported to target tissue. And it is linear increase follow gene or medicine input amount in certain range.
Owner:CHONGQING MEDICAL UNIVERSITY
DSPE-PEG-FA-modified nanometer paclitaxel liposome and preparation method thereof
InactiveCN102188382AHigh encapsulation efficiencyGuaranteed purityOrganic active ingredientsPharmaceutical non-active ingredientsPaclitaxel InjectionDspe peg
The invention relates to a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. A molar ratio of the DSPE-PEG2000-FA to egg yolk lecithin is 0.05% to 0.15%, and a particle size of the liposome is less than 150 nm. A preparation method of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome comprises the following steps: first, preparing a DSPE-PEG2000-FA into a DSPE-PEG2000-FA micelle; second, performing incubation on the phosphatidyl ethanolamine-polyethylene glycol2000-folic acid micelle and a paclitaxel liposome together to obtain a DSPE-PEG2000-FA-modified nanometer paclitaxel liposome. Materials, which are forbidden to be used in clinical practice, are not used as crude materials in the present invention. According to the invention, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has a small particle size, and the content of the DSPE-PEG2000-FA is low; besides, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome has good drug entrapment efficiency and good colloid stability. Moreover, the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome can be absorbed effectively by an ovarian cancer cell having properties of sensitiveness to folic acid (+) and drug resistance, and the cytotoxicity of folic acid dependence is displayed; therefore, the efficacy of the DSPE-PEG2000-FA-modified nanometer paclitaxel liposome is stronger than that of a paclitaxel injection.
Owner:李红霞
Nano drug delivery system containing polymer and phospholipid and preparation method thereof
ActiveCN103040724AGood biocompatibilityControllable biodegradationOrganic active ingredientsPharmaceutical delivery mechanismBiocompatibility TestingPolyethylene glycol
The invention relates to a nano drug delivery system containing polymer and phospholipid. The system comprises polylactic-co-glycolic acid, phospholipid, drug and linear polymer of distearoyl phosphatidyl ethanolamine, polyethylene glycol and folic acid, wherein the drug is coated by the polylactic-co-glycolic acid to form a core; the phospholipid surrounds the surface of the polylactic-co-glycolic acid to form an intermediate layer; and the linear polymer of the distearoyl phosphatidyl ethanolamine, the polyethylene glycol and the folic acid uses the distearoyl phosphatidyl ethanolamine to interleave in the phospholipid intermediate layer to form an outer layer to provide a shell of the polyethylene glycol and a targeting ligand of the folic acid. The Nano drug delivery system containing polymer and phospholipid has comprehensive advantages of the polymer and a nano-liposome, has the advantages of good biocompatibility, controllable biodegradability and low toxicity of degradation products, capacities of easily realizing targeted controlled release and achieving surface functionalization, and the like. In addition, the invention further provides a preparation method of the nano drug delivery system containing the polymer and the phospholipids, which is simple and convenient to operate.
Owner:珠海中科先进技术研究院有限公司
Amphipathilic block polymer micelle nano medicament carrying system and preparation method
InactiveCN101829046AHigh encapsulation efficiencyDrug loadingOrganic active ingredientsPharmaceutical delivery mechanismPolyethylene glycolEntrapment
The invention relates to a method for increasing medicament carrying amount and entrapment rate of polymer micelles on an anti-tumor medicament by using hydrophobic molecules. The polymer micelles are prepared from amphipathilic polymer such as polyethylene glycol-phosphatidyl ethanolamine (PEG-DSPE) by a membrane hydration method, and the micelles can be used for wrapping insoluble or low water-soluble anti-tumor medicaments for chemotherapy of tumor. Compared with the polymer micelles prepared without adding hydrophobic molecules, the polymer micelles obtained by adding the hydrophobic molecules such as phospholipid molecules with longer aliphatic chains (10 to 20 carbon atoms) in a certain proportion during preparing the polymer micelles by using the membrane hydration method obviously increase the entrapment rate and the medicament carrying amount on the raw material medicaments of the anti-tumor medicaments. The entrapment rate increment of the polymer micelles on the raw material medicaments improves the utilization rate of the raw material medicaments, and the medicament carrying amount of the polymer micelles improves the efficiency of medicament transmission during treating the tumor so as to lay a foundation for further increasing the curative effect of the anti-tumor medicament.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
Tetravinyl-based Gemini type amphiphilic compound as well as preparation method and application thereof
ActiveCN106432203AHas aggregation-induced luminescent propertiesFacilitates the study of transfection mechanismsOrganic chemistryOther foreign material introduction processesFluorescenceMass spectrometry
The invention discloses a tetravinyl-based Gemini type amphiphilic compound as well as a preparation method and application thereof. The compound disclosed by the invention is mainly prepared through McMurry coupling reaction, nucleophilic substitution reaction and Click reaction; the structure of the compound is also confirmed through infrared, nuclear magnetic and mass-spectrum ways; in an aqueous solution, molecules of a derivative of the compound disclosed by the invention self-assemble to form aggregation-induced fluorescence-enhanced micelles (AIE micelles); the compound acts with a nucleic acid, and then can co-aggregate to form nano particles easy for cellular uptake; green fluorescent protein (GFP) and luciferase (Luciferase) expression assays prove that the compound self and a liposome formed with dioleoyl phosphatidyl ethanolamine (DOPE) can be used as non-viral gene vectors; meanwhile, the derivative is successfully used for tracing the cellular uptake and release processes of pGL-3 and FAM-DNA by utilizing the reversible transformation between the self-assembly of the compound and the co-assembly with DNA (Deoxyribonucleic Acid).
Owner:BEIJING NORMAL UNIVERSITY
Robust controlled-release formulations
ActiveUS20140348903A1Aggregation is suppressedImprove efficiencyAntibacterial agentsOrganic active ingredientsLiquid crystallinePre formulation
Owner:CAMURUS AB
Folate-mediated targeted polymeric micelle
InactiveCN101721350AHigh antitumor activity in vitroOrganic active ingredientsPharmaceutical delivery mechanismDrug carrierCell growth
The invention belongs to the field of medicinal preparations and relates to a folate-mediated targeted polymeric micelle, in particular to the folate-mediated targeted polymeric micelle which entraps an insoluble anti-tumor medicament. The folate-mediated targeted polymeric micelle is prepared from two biocompatible materials, namely folate-polyethyleneglycol-phosphatidyl ethanolamine and methoxypolyethyleneglycol-phosphatidyl ethanolamine in a certain proportion, and entraps the insoluble anti-tumor medicament, so that the insoluble anti-tumor medicament is solubilized in the prepared polymeric micelle effectively. Experiments prove that the folate-mediated targeted polymeric micelle has the advantages of specifically targeting to inhibit the growth of tumor cells and effectively avoiding macrophage phagocytose and providing an ideal novel medicament carrier and preparation for the insoluble anti-tumor medicament.
Owner:FUDAN UNIV
Preparation methods of distearoyl phosphatidyl ethanolamine and amino polyethylene glycol derivatives thereof
ActiveCN101805369AEasy to operateLow costPhosphatide foodstuff compositionsBulk chemical productionPhosphorylcholinePolyethylene glycol
The invention discloses preparation methods of distearoyl-phosphoethanolamine and amino polyethylene glycol derivatives thereof and relates to effective preparation methods of a medicinal carrier material phospholipids-distearoyl-phosphoethanolamine (DSPE for short) and amino polyethylene glycol derivatives of the distearoyl-phosphoethanolamine (NH2-PEG-DSPE for short). The preparation method of the distearoyl-phosphoethanolamine comprises the following steps of: firstly reacting phosphorus oxychloride with 1,2-distearoyl-glyceride to obtain phosphorylcholine monoester which is I for short; reacting the phosphorylcholine monoester with 2-hydroxyethyl-benzyqcarbamate to obtain DSPE containing amino-protecting group which is II for short; and carrying out catalytic hydrogenation on the II to remove the protecting group to obtain DSPE. The preparation method of the amino polyethylene glycol derivatives of the distearoyl-phosphoethanolamine comprises the following steps of: reacting DSPE with nitrine substituted PEG chloro-carbonic ester which is VI for short to obtain nitrine-polyethylene glycol DSPE derivatives which is III for short; and reducing the nitrine into amino by catalytic hydrogenation to obtain the amino polyethylene glycol derivatives of the distearoyl-phosphoethanolamine.
Owner:SOUTHEAST UNIV +1
Method for preparing high-content phosphatidyl ethanolamine
ActiveCN104592293AAchieve decolorizationTo achieve impurity removalPhosphatide foodstuff compositionsAlkaneHplc method
The invention discloses a method for preparing high-content phosphatidyl ethanolamine. The method comprises the following steps of dissolving a cephalin crude product as a raw material with an organic solvent, eluting twice with a ternary mixed solvent comprising polyhalogenated alkanes, lower alcohol and water by column chromatography and drying to obtain the phosphatidyl ethanolamine product, wherein the obtained phosphatidyl ethanolamine product is high in content (96.0%-99.9% obtained by an HPLC method), low in content of impurities (in which the content of phosphatidylcholine is less than 0.5%, the content of lysophosphatidylcholine is less than 0.5 %, the content of free fatty acid is less than 0.2%, and the content of triglyceride is less than 0.2%), low in oxidation indexes (of which the acid number is less than 1.0, the peroxide value is less than 1.0 and the anisidine value is less than 5.0), and the product quality meets the quality requirements of drug phospholipid for injecting.
Owner:GUANGZHOU HANFANG PHARMA
Propranolol hydrochloride lipidosome gel and preparation method thereof
ActiveCN103622903AImprove stabilityProlonged dosing timeOrganic active ingredientsAerosol deliveryWhole bodyCholesterol
The invention discloses a propranolol hydrochloride lipidosome gel, which is prepared by the following bulk drugs and auxiliary materials by weight percent: 0.012-0.075% of propranolol hydrochloride, 0.037-0.150% of phosphatidyl ethanolamine, 0.012-0.075% of cholesterol, 2.5-5% of triethanolamine, 1-2% of carbopol, and the balance of water. According to the propranolol hydrochloride lipidosome gel, during the preparation, the lipidosome is uniformly dispersed in the gel, so that the stability of the lipidosome is improved; the water-soluble gel carbopol has excellent biocompatibility, can be well adhered to skin and cannot stimulate skin; drug administration time is prolonged, the toxic and side effects on the whole body are reduced, the adaptability of patients is improved, and the propranolol hydrochloride lipidosome gel has excellent application prospect.
Owner:SHANDONG UNIV
Lipid microvesicle ultrasound angiography powder agent internally containing mixture gas of fluorine carbon/nitrogen gas and production of the same
InactiveCN101130095AEnhanced Ultrasound ImagingEnables mass productionEchographic/ultrasound-imaging preparationsLipid formationDispersity
The invention discloses a hollow lipid microfoam composition with fluorocarbon / nitrogen and preparing method, wherein the microfoam filming material is composed of phosphatide, protective and polymer; the phosphatide is selected from phosphatidyl Choline and phosphatidyl ethanolamine; the protective can be middle and macromolecular hydroxyethyl amidon; the polymer is selected from boluoshamu 188 or medically acceptable surface activator for vein injection; the lipid filming material covers the fluorocarbon liquid to form emulsion particle, which forms hollow lipid microball under high temperature instantaneously through gasifying the liquid fluorocarbon; the fluorocarbon / nitrogen is guided to produce the lipid microball for ultrasonic imaging with effectively reinforcing time over 60 min. The invention has high yield rate and fast manufacturing speed, which improves the microball dispersity and microball density effectively.
Owner:CHONGQING RUNQI PHARMA TECH DEV
Method for detecting lipid molecules in salmon
ActiveCN105911131AEasy to useSimple and fast operationPreparing sample for investigationMaterial analysis by electric/magnetic meansOrganic solventElution
The invention discloses a method for detecting lipid molecules in salmon. The method includes the following steps that firstly, a sample is processed in advance, wherein salmon meat is cleaned and ground into meal, an organic solvent I is added into the salmon meal to be shaken and evenly mixed, ultrasonic ice bath extraction is conducted, pure water is added after extraction to be shaken and evenly mixed, the obtained mixture is centrifuged by a freezing centrifugal machine, a bottom-phase solution is obtained, dried at low temperature and dissolved again by means of an organic solvent II, and a lipid crude extract is obtained; secondly, enrichment and purification are conducted, wherein a solid-phase extraction column is activated, then the lipid crude extract is subjected to sample loading, spraying and elution, and the collected elution solution is a lipid extraction solution; thirdly, the lipid extraction solution is subjected to mass spectrometric detection and analysis. By means of the method, structure verification and quantitative analysis of phosphatidylcholine (PC) and phosphatidyl ethanolamine (PE) in salmon can be achieved.
Owner:ZHEJIANG GONGSHANG UNIVERSITY
Dequalinium chloride-polyethylene glycol-distearoyl phosphatidyl ethanolamine conjugated compound and resveratrol liposome modified thereby
InactiveCN102757555AAvoid drug resistanceIncrease intakeHydroxy compound active ingredientsRespiratory disorderYolkCholesterol
The invention discloses a DQA-PEG 2000-DSPE (Dequalinium Chloride-Polyethylene Glycol-Distearoyl Phosphatidyl Ethanolamine) conjugated compound and resveratrol liposome modified thereby. The structural formula of the compound is shown by a formula I. In terms of composition, the resveratrol liposome comprises resveratrol and a fat material, wherein the mass ratio of the resveratrol to the fat material is (1:20)-(1:40); and the fat material consists of egg yolk lecithin, cholesterol and the compound shown by the formula I in the molar ratio of (63-67):(18-22):(2-4.35) in sequence. Pharmacodynamic tests prove that mitochondrial targeted resveratrol liposome has an extremely strong cell toxic effect in in-vitro cell experiments of human lung adenocarcinoma A549 cells and drug-resistant A549 / cDDP cells thereof, a tumor sphere model and an in-vivo transplantation tumor model and can penetrate through the core of the tumor sphere. The anti-tumor effect of vinorelbine liposome on the drug-resistant A549 / cDDP cells can be obviously improved by combining the resveratrol liposome with the vinorelbine liposome for use (formula I).
Owner:PEKING UNIV
Folate-targeted hydrophobic medicine-loaded polymeric vesicle and preparation method and use thereof
InactiveCN101953778AFlexibleGood flexibilityPharmaceutical delivery mechanismPharmaceutical non-active ingredientsFreeze-dryingPolyethylene glycol
The invention discloses a folate-targeted hydrophobic medicine-loaded polymeric vesicle and a preparation method and use thereof. The polymeric vesicle is prepared by the following steps of: (1) dissolving amphiphilic triblock copolymer and a hydrophobic medicine in an organic solvent, adding distearamide phosphatidyl ethanolamine-polyethylene glycol (2000) folate, evaporating to remove the organic solvent to prepare a uniform thin film, blowing and drying; and (2) adding double distilled water and products in the step (1) into a container, hydrating, shaking and uniformly mixing to ultrasonically form stable emulsion, performing film filtering, collecting filter liquor and performing freeze drying, The polymeric vesicle has main advantages of liposome, nanoparticles and other particle medicine-loaded systems, stability in vivo and in vitro obviously superior to the liposome, thicker film layer, contribution to encapsulating the hydrophobic medicine, dual-targeting function of EPR passive targeting and folate active targeting, and capacity of making the medicine-loaded vesicle effectively targeted and gathered on a tumor part and fulfilling the aim of targeted therapy.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI
99mTc-labeled 19 amino acid containing peptide for use as phosphatidylethanolamine binding molecular probe and radiopharmaceutical
With only 19 amino acids, Duramycin is the smallest known polypeptide that has a defined 3-dimmensional binding structure. Duramycin binds Phosphatidylethanolamine (PtdE) at a 1:1 ratio with high affinity and exclusive specificity. As an abundant binding target, PtdE is a major phospholipid and accounts for about 20 % of the phospholipid content in mammalian cellular membranes. PtdE is externalized to the surface of apoptotic cells, and also becomes accessible in necrotic cells due to compromised plasma membrane integrity. Given the unique physicochemical properties of Duramycin and the availability of PtdE in acute cell death, the goal of this study is to develop and evaluate 99mTc-HYNIC-Duramycin as a novel molecular probe for imaging PtdE. 99mTc-HYNIC-Duramycin is a low-molecular weight, fast-clearing radiopharmaceutical that detects apoptosis / necrosis by binding to PtdE. The goal was to quantify the uptake of 99mTc-HYNIC-Duramycin in the area-at-risk after myocardial ischemia and reperfusion, and to determine the window of detection.
Owner:MCW RES FOUND INC
Quercetin hydroxypropyl Beta-cyclodextrin inclusion liposome, preparation method and application thereof
InactiveCN102058536AImprove bioavailabilityExtend cycle timeOrganic active ingredientsPowder deliveryCholesterolPolyethylene glycol
The invention relates to a quercetin hydroxypropyl Beta-cyclodextrin inclusion liposome, a preparation method and application thereof, belonging to the field of pharmaceutical preparation. The invention provides a medicine capable of improving the bioavailability of quercetin and a preparation method of the medicine. The medicine capable of improving the bioavailability of the quercetin is the quercetin hydroxypropyl Beta-cyclodextrin inclusion liposome which is prepared from the following components in parts by weight and a pharmaceutically-acceptable solvent: 1 part of quercetin, 1-100 parts of hydroxypropyl Beta-cyclodextrin, 5-50 parts of granulesten, 1-10 parts of cholesterol and 0.1-5 parts of polyethylene glycol-distearin phosphatidyl ethanolamine.
Owner:SICHUAN UNIV
Diet supplement for causing rapid weight loss, controlling appetite, managing stress, supporting relaxation, combating fatigue and supporting mental well-being.
InactiveUS20070237786A1Fast weighingAppetite suppressantBiocideMetabolism disorderDietary supplementMental health
Owner:SMARTBURN FORMULATIONS LTD
Blood coagulant for blood collection container
ActiveCN102212514ALong storage timeCoagulation rate is less affected by temperatureEnzyme stabilisationBiological testingBlood Collection TubeHemolysis
Owner:SHANGHAI KEHUADIAGNOSITIC MEDICAL PRODS
Etomidate pharmaceutical composition and preparation method thereof
ActiveCN104644554ALess quantityImprove stabilityOrganic active ingredientsNervous disorderEtomidateEthanolamine synthesis
The invention relates to an etomidate pharmaceutical composition, which comprises the following raw materials in parts by weight: 1 part of etomidate, 50-100 parts of injection oil, 3-9 parts of phospholipid and 250-1,000 parts of injection water, wherein the content of phosphatidylcholine in the phospholipid is greater than or equal to 75% (w / w); and the content of phosphatidyl ethanolamine is smaller than or equal to 15 (w / w). The etomidate pharmaceutical composition provided by the invention has relatively high stability.
Owner:BEIJING LANDAN PHARMA TECH
Process for preparing high purity soy phoshatidylcholine without lysophosphatide
InactiveCN1837222AEasy to manufactureWide range of usesPhosphatide foodstuff compositionsSolventSoybean Phospholipids
The invention discloses a high-purity soya bean phosphatidyl choline without lysophosphatide preparing method in the phosphatide technique domain, which comprises the following steps: using soybean podwer phosphatide for raw material; extracting by dissolvant; freezing raffinate; treating liquor by dual column chromatogram; eluting for treating column 1; dislodging phosphatidyl ethanolamine; eluting and treating column2; dislodging lysophosphatide, wherein eluent of dissolvant,column 1 and column 2 for extracting is common single solvent; the production has no lysophosphatide; the bilineurine content of soya bean lecithin is more than 90%.
Owner:JIANGNAN UNIV
Metabolic marker for diagnosing coronary heart disease
InactiveCN105486773AEasy diagnosisImprove accuracyComponent separationDisease diagnosisCoronary arteriesCoronary heart disease
The invention discloses a metabolic marker for diagnosing a coronary heart disease. The metabolic marker comprises one or more of 1-palmitoyl-sn-glycerinum-3-phosphatidylcholine, 1-octadecatetraenoicenoyl-sn-glycerinum-3-phosphatidylcholine, 1-linoleoyl-sn-glycerinum-3-phosphatidylcholine, 1-stearoyl-sn-glycerinum-3-phosphatidylcholine, 1-linoleoyl-2-hydroxy-sn-glycerinum-3-phosphatidyl ethanolamine, 1-linoleoyl-sn-glycerinum-3-phosphatidylcholine, 1-oleoyl-sn-glycerinum-3-phosphatidylcholine, 1-hexadecene acyl-sn-glycerinum-3-phosphatidylcholine, phytosphingosine and hexadecanamide. The metabolic marker provided by the invention can accurately diagnose the coronary heart disease, accurately distinguish patients with the coronary heart disease and healthy persons, can also accurately distinguish the patients with the coronary heart disease from patients with atherosclerosis of coronary artery, and has high accuracy, sensitivity and specificity.
Owner:齐炼文
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com